The management of patients with a selective IgA deficiency currently consists ofsymptomatic treatment with treatment of infections by occasional or prolonged antibiotictherapy, immunosuppressive treatments for autoimmune pathologies, symptomatic treatmentof allergic manifestations.IVIG supplements are sometimes proposed in the event of recurrent infections and thedemonstration of deficiencies in IgG subclasses (IgG1, 2, 3) often not sought fordiagnosis The factors associated with the severity of clinical manifestations are notwell identified and patients with IgA deficiency must be monitored over the long termbecause of the risk of the appearance of autoimmune manifestations and neoplasia. Theidentification of such factors could lead to the proposal of close monitoring for thesepatients.IgA deficiency, which is frequent, has not been identified as a risk factor for severeCOVID-19 infection, probably due to a lack of studies with sufficient recruitment. Thetherapeutic attitude concerning patients with an IgA deficiency in the event of COVID-19infection is therefore not consensual.There is currently no action to be taken regarding the risk of transmission of IgAdeficiency.